uniQure’s four-year AMT-130 Huntington’s disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations.

NEW YORK, Sept. 29, 2026 /PRNewswire/ — Shares of uniQure N.V. (NASDAQ: QURE) opened down a sharp 39% on September 29, 2026, after the Company’s 48-month AMT-130 Huntington’s disease data showed a smaller treatment benefit than the one reported at three years. If you lost money on QURE, you have legal rights, and those rights do not end because you already sold. QURE investors who suffered losses are encouraged to submit their loss information now or contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

AMT-130 is uniQure’s lead pipeline candidate. Reportedly, the drug showed only a “44% slowing of disease progression” at 48 months under the composite Uniform Huntington’s Disease Rating Scale, as compared to a 75% slowdown the company had reported at 36 months.

Shares spiked in June when uniQure announced its intentions to submit an application tot he FDA to bring the drug to market. On September 2, the Company did just that, submitting a Biologics License Application (BLA) based upon the three-year data analysis, just weeks before the four-year results were unveiled.

SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of uniQure shareholders. Shareholders who lost money on uniQure stock may request a free review of their QURE losses, or reach Joseph E. Levi, Esq. by email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the QURE Investigation

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether uniQure made materially false or misleading statements about its AMT-130 Huntington’s disease program, including its clinical results and their durability. On September 29, 2026, the Company released 48-month AMT-130 data showing a smaller treatment benefit than at three years, and the stock price declined sharply.

Q: When did uniQure allegedly mislead investors?A: The investigation concerns statements made before uniQure’s September 29, 2026 release of 48-month AMT-130 data. These statements allegedly caused investors to purchase securities at inflated prices.

Q: What do QURE investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my QURE shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought QURE and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence. uniQure shares trade on NASDAQ under the ticker QURE.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/uniqure-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-uniqure-qure-302893560.html

SOURCE SueWallSt.com